www.LupusTreatmentReport.com
https://clinicaltrials.gov/ct2/show/NCT03917797?type=Intr&cond=Lupus&phase=012345&lupd_s=04%2F03%2F2019&lupd_d=14
Conditions : Lupus Erythematosus, Systemic; Lupus Glomerulonephritis
Interventions : Biological: MSC treatment; Drug: Standard of Care; Drug: Placebo
Sponsor : Universidad de los Andes, Chile
Recruiting
Mesenchymal Stromal Cells (MSC´s) in Renal Lupus
NCT03917797
Wed, 17 Apr 2019 12:00:00 EDT
https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-019-0156-0
https://www.ncbi.nlm.nih.gov/pubmed/30923617?dopt=Abstract
Related Articles
Novel insights into MSC-EVs therapy for immune diseases.
Biomark Res. 2019;7:6
Authors: Lai P, Weng J, Guo L, Chen X, Du X
Abstract
Mesenchymal stromal cells (MSC) are a heterogeneous cell population with self-renewal and the ability to differentiate into different lineages. The novel regulatory role of MSC in both adaptive and innate immune responses got extensive investigation and MSC have been widely used in clinical trials as immunosuppressive agents for autoimmune and inflammatory diseases, including graft-versus-host disease (GVHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), chronic kidney disease, etc. Recent studies have found that MSC exerted their immunomodulation function through secreting extracellular vesicles (EVs), which delivered parent cell cargo to recipient cells without oncogenicity or variability. Since MSC-EVs exhibit most of the properties of MSC and take advantage of their cellular immunomodulatory fuction, MSC-EVs appear to a promising none-cell therapy in various human diseases. In this review, we summarize the pivotal roles of MSC-EVs as agents for immunotherapy in diseases.
PMID: 30923617 [PubMed]
PubMed:30923617
